Explain this page
Arphra AIPlain-English read on AbbVie Inc.’s valuation06-09today
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection7h
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection7h
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis9h
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis9h
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$1,652.36
+618.23% vs spot
Recommendation
Strong Buy
15 of 17 methods
Method spread
4bull10bear
±5% threshold
Analyst PT consensus: $257.54 (+11.94%)
Candlestick · 1Y
Open in chart workstation →ABBV
216.49+17.81%H 244.81L 181.73MA50 211.77MA200 220.57Avg vol 6.2M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.27% | +3.93% | +6.66% | +12.26% | +0.56% | +0.69% | +25.20% | +69.26% | +101.81% | +275.24% | +557.31% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$34.15M
10 txns
Net flow
−$34.15M
Aftermarket
LiveLast trade
$231.09
282 sh
Bid
$230.91
200 sh
Ask
$232.92
2 sh
Spread
$2.010
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $15B | $699M | $0.39 |
| Q4 Dec 2025 | $16.62B | $1.82B | $1.02 |
| Q3 Sep 2025 | $15.78B | $186M | $0.10 |
| Q2 Jun 2025 | $15.42B | $938M | $0.53 |
| Q1 Mar 2025 | $13.34B | $1.29B | $0.72 |
| Q4 Dec 2024 | $15.1B | -$22M | $-0.02 |
Sector & industry today
LiveSectors
- Real Estate+1.26%
- Industrials+1.00%
- Basic Materials+0.65%
- Energy+0.59%
- Healthcare+0.01%
- Utilities-0.07%
- Financial Services-0.24%
- Communication Services-0.55%
- Technology-0.80%
- Consumer Cyclical-0.85%
- Consumer Defensive-1.00%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.19%
- Biotechnology+6.56%
- Financial - Mortgages-4.05%
- Electrical Equipment & Parts+3.88%
- Staffing & Employment Services-3.62%
- Software - Services-3.30%
- Software - Infrastructure-3.07%
- Advertising Agencies+2.92%
- Apparel - Footwear & Accessories-2.80%
- Engineering & Construction+2.80%
- Financial - Conglomerates+2.62%
- Luxury Goods+2.47%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$257.54
+11.94% upside
Low
$223.00
Median
$260.00
High
$298.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infectionprnewswire.com·Jun 23, 2026
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infectionprnewswire.com·Jun 23, 2026
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasisprnewswire.com·Jun 23, 2026
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasisprnewswire.com·Jun 23, 2026
- Why AbbVie Stock Jumped Todayfool.com·Jun 22, 2026
- AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?fool.com·Jun 22, 2026
- Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offerfool.com·Jun 22, 2026
- AbbVie Inc (ABBV) Shares Surge 6.2% -- What GF Score of 82 Tells Investorsgurufocus.com·Jun 22, 2026
Recent analyst activity
DB- Jun 22, 2026PT$260.00AbbVie bid for Apogee Therapeutics makes sense, says Wells FargoWells Fargo
Financial scores
DBJun 19, 2026Altman Z
2.58
Grey
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
7/9
Strong
≥ 7 strong · 4–6 average · < 4 weak
Peers
Total assets
$133.96B
Total debt
$69.07B
Cash & equiv
$5.23B
Operating CF
$19.03B
Free cash flow
$17.82B
Buybacks
-$980M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Purdue David Ryan officer: SVP, Controller | Sell | 5,230 | $1.22M | Mar 04, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 5,777 | $1.35M | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 2,600 | $611.68K | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 10,291 | $2.41M | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 22,381 | $5.15M | Feb 25, 2026 |
SALEKI-GERHARDT AZITA officer: EVP, CHIEF OPERATIONS OFFICER | Sell | 42,370 | $8.41M | Aug 12, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $61.16B | $20.09B | $4.23B | $2.37 | +6.91% |
| FY 2024 | $56.33B | $9.14B | $4.28B | $2.39 | +7.59% |
| FY 2023 | $54.32B | $12.76B | $4.86B | $2.72 | +8.95% |
| FY 2022 | $58.05B | $18.12B | $11.84B | $6.63 | +20.39% |
| FY 2021 | $56.2B | $17.92B | $11.54B | $6.45 | +20.54% |